Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 3
2(40.0%)
5Total
Phase 1(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07307794Phase 1Recruiting

To Evaluate the Adhesion of TK-254RX on Healthy Participants

Role: collaborator

NCT06866613Phase 3Completed

Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.

Role: collaborator

NCT06871046Phase 3Completed

Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions

Role: collaborator

NCT06870422Phase 1Completed

To Assess the Effect of the Special Condition on the Pharmacokinetics and Tolerability of the Esflurbiprofen Topical System (EFTS) in Healthy Volunteers.

Role: collaborator

NCT06823284Phase 1Completed

To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects

Role: collaborator

All 5 trials loaded